AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Soligenix shares surge 106.40% intraday after completing Phase 2a proof of concept study for SGX945 in Behcet's Disease.
ByAinvest
Thursday, Jul 31, 2025 10:17 am ET1min read
Soligenix, Inc. surged 106.40% intraday, with the company announcing the completion of its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behcet's Disease. The study demonstrated biological efficacy, supporting the advancement of SGX945 in this difficult-to-treat orphan disease. The positive results from the clinical trial indicate potential anti-tumor activity and safety, which aligns with the significant increase in the stock price.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet